Millennium Management’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

Millennium Management’s Portfolio OSIR Stock Details OSIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-337,701	Closed	-$6.42M	–	4789
2019 Q1	$6.42M	Buy	337,701 +304,385	+914%	+$4.94M	0.01%	1584
2018 Q4	$450K	Buy	33,316 +15,805	+90%	+$177K	﹤0.01%	3030
2018 Q3	$194K	Buy	+17,511	New	+$175K	﹤0.01%	3650
2017 Q1	–	Sell	-208,979	Closed	-$1.03M	–	4158
2016 Q4	$1.03M	Buy	+208,979	New	+$1.07M	﹤0.01%	2231
2016 Q2	–	Sell	-34,373	Closed	-$196K	–	3949
2016 Q1	$196K	Buy	34,373 +16,441	+92%	+$115K	﹤0.01%	2960
2015 Q4	$186K	Buy	+17,932	New	+$243K	﹤0.01%	3117
2015 Q3	–	Sell	-35,850	Closed	-$698K	–	4060
2015 Q2	$698K	Buy	35,850 +9,543	+36%	+$169K	﹤0.01%	2466
2015 Q1	$462K	Buy	26,307 +2,069	+9%	+$34.8K	﹤0.01%	2803
2014 Q4	$388K	Sell	24,238 -22,377	-48%	-$300K	﹤0.01%	3179
2014 Q3	$587K	Buy	+46,615	New	+$665K	﹤0.01%	2657

Other funds holding OSIR

FGAM

Financial Gravity Asset Management Lakeway, Texas $562M AUM

Millennium Management's OSIR Position: Q2 2019 in Review

Millennium Management sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q2 2019, closing a stake of 337,701 shares — an estimated $6.42M sold.

Millennium Management first reported a position in OSIR in Q3 2014 and held it in 10 quarters. The position peaked at $6.42M in Q1 2019. 1 fund tracked by Wall St. Rank holds OSIR as of Q2 2019.

Millennium Management reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Millennium Management sold 337,701 Osiris Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $6.42M.
Millennium Management first reported a position in Osiris Therapeutics, Inc. Common Stock in Q3 2014 and held it in 10 quarters.
Millennium Management's Osiris Therapeutics, Inc. Common Stock position peaked at $6.42M in Q1 2019.
1 fund tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Millennium Management's 13F filing for Q2 2019, filed 14 Aug 2019.